Alan F List

US Patent:

20060128716, Jun 15, 2006

Filed:

Sep 23, 2003

Appl. No.:

10/528914

Inventors:

Margaret Dugan - Woodside NY, US
Alan List - Tucson AZ, US

International Classification:

A61K 31/501

US Classification:

514252030, 514252040

Abstract:

The present invention relates to a method of treating myelodysplastic syndromes comprising administering a therapeutically effective amount of a 4-pyridylmethyl-phthalazine derivative to a warm-blooded animal in need thereof.

US Patent:

20120316081, Dec 13, 2012

Filed:

Jul 30, 2012

Appl. No.:

13/561687

Inventors:

Alan F. List - Tampa FL, US
Lubomir Sokol - Tampa FL, US

Assignee:

H. Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa FL

International Classification:

C40B 30/04
C12Q 1/68

US Classification:

506 9, 435 612, 435 611

Abstract:

Myelodysplastic syndromes display both hematological and biological heterogeneity with variable leukemia potential. To determine whether microRNAs expression offers diagnostic discrimination or influences malignant potential in MDS, bone marrow miRNA expression was investigated from prognostically distinct MDS subsets using a microarray platform. After background subtraction and normalization, data were analyzed indicating thirteen miRNA signature with statistically significant differential expression, including down-regulation of members of a leukemia associated miRNA family. A unique signature consisting of 10 miRNAs was closely associated with International Prognostic Scoring System risk category permitting discrimination between lower and higher risk disease. Selective overexpression of miRNA-181 family members was detected in higher risk MDS, indicating pathogenetic overlap with acute myeloid leukemia. Analysis of miRNA expression profile offers diagnostic utility, and provides pathogenetic and prognostic discimination in MDS.

US Patent:

58469583, Dec 8, 1998

Filed:

Feb 17, 1995

Appl. No.:

8/390713

Inventors:

Robert L. Capizzi - Haverford PA
Alan F. List - Tucson AZ

Assignee:

U.S. Bioscience, Inc. - West Conshohocken PA
Arizona Board of Regents on Behalf of the University of Arizona - Tucson AZ

International Classification:

A61K 3166

US Classification:

514114

Abstract:

The present invention relates to methods of stimulating the growth of hematopoietic progenitor cells. In particular, it relates to the use of thiols and related compounds in stimulating the growth of hematopoietic progenitor cells in vitro and in vivo. Furthermore, the present invention relates to methods of using these compounds for the treatment of marrow failure states and immunodeficient conditions, including but not limited to myelodysplastic syndromes and acquired immunodeficiency syndrome.

US Patent:

59069848, May 25, 1999

Filed:

Mar 24, 1998

Appl. No.:

9/046870

Inventors:

Robert L. Capizzi - Haverford PA
Alan F. List - Tucson AZ

Assignee:

Arizona Board of Regents on behalf of The University of Arizona - Tucson AZ
U.S. Bioscience - West Conshohocken PA

International Classification:

A61K 3166
A61K 3113

US Classification:

514114

Abstract:

The present invention relates to methods of stimulating he growth of hematopoietic progenitor cells. In particular, it relates to the use of thiols and related compounds in stimulating the growth of hematopoietic progenitor cells in vitro and in vivo. Furthermore, the present invention relates to methods of using these compounds for the treatment of marrow failure states and immunodeficient conditions, including but not limited to myelodysplastic syndromes and acquired immunodeficiency syndrome.

US Patent:

20220323433, Oct 13, 2022

Filed:

Mar 4, 2022

Appl. No.:

17/687231

Inventors:

Alan F. LIST - Tampa FL, US
David A. SALLMAN - Tampa FL, US
John S. KOVACH - Pasadena CA, US

Assignee:

H. Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa FL
Lixte Biotechnology, Inc. - Pasadena CA

International Classification:

A61K 31/496
A61P 35/02

Abstract:

This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/mto 5 mg/mof a compound having the structureor a salt, zwitterion, or ester thereof.

US Patent:

20210253664, Aug 19, 2021

Filed:

Feb 22, 2021

Appl. No.:

17/181246

Inventors:

- Tampa FL, US
Alan F. List - Tampa FL, US

International Classification:

C07K 14/705
A61P 35/00
G01N 33/574

Abstract:

Myelodysplastic syndrome (MDS) hematopoietic stem and progenitor cells (HSPC) translocate endosomal Toll-Like receptor (TLR)-9 to the plasma membrane, thereby sensitizing these clonal propagating cells to respective ligands in the microenvironment. TLR9 is the cognate receptor for RNA:DNA hybrids (R-loops) and unmethylated CpG oligonucleotides in oxidized mitochondrial DNA, the latter of which is abundant in the bone marrow microenvironment as a result of massive medullary pyroptotic cytolytic cell death. Both ligands are important danger-associated molecular patterns (DAMPs) triggering innate immune activation and chronic inflammation that contributes to MDS pathogenesis. In an effort to neutralize these DAMPs and disrupt this feed-forward inflammatory cascade, a chimeric protein was designed fusing the external epitopes of TLR9 to the Fc domain of human IgG4 to serve as a decoy receptor or ligand trap recognizing extracellular RNA:DNA hybrids (R-loops) and oxidized mitochondrial DNA.

US Patent:

20200354331, Nov 12, 2020

Filed:

Jun 18, 2019

Appl. No.:

16/444564

Inventors:

- Tampa FL, US
Alan List - Tampa FL, US
Nicholas Lawrence - Tampa FL, US

International Classification:

C07D 311/30
C07D 311/62
C07D 239/91
C07H 17/07

Abstract:

Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-VIII as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.

US Patent:

20200115358, Apr 16, 2020

Filed:

Mar 13, 2017

Appl. No.:

16/083547

Inventors:

- Tampa FL, US
Alan List - Tampa FL, US
Nicholas Lawrence - Tampa FL, US

International Classification:

C07D 311/30
A61K 31/352
A61K 45/06
C07D 493/04
A61K 47/54

Abstract:

Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-V as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.